-
1
PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors
Published 2019-08-01Subjects: Get full text
Article -
2
Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy
Published 2020-08-01Subjects: “…combinatorial immunotherapy…”
Get full text
Article -
3
Intratumoral Treatment of Melanoma Tumors with Large Surface Area Microparticle Paclitaxel and Synergy with Immune Checkpoint Inhibition
Published 2024-01-01Subjects: Get full text
Article -
4
Using nanoparticles for in situ vaccination against cancer: mechanisms and immunotherapy benefits
Published 2020-12-01Subjects: “…anti-tumor immunity; combinatorial immunotherapy; therapeutic devices…”
Get full text
Article -
5
The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues
Published 2022-01-01Subjects: Get full text
Article -
6
Indoleamine 2,3-Dioxygenase 1 Inhibitor-Loaded Nanosheets Enhance CAR-T Cell Function in Esophageal Squamous Cell Carcinoma
Published 2021-03-01Subjects: Get full text
Article -
7
Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy
Published 2018-07-01Subjects: Get full text
Article -
8
α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcino...
Published 2019-03-01Subjects: “…α-TGFβ /α-PD-1 combinatorial immunotherapy…”
Get full text
Article -
9
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Published 2023-10-01Subjects: Get full text
Article